Pharmaceutical manufacturer Eli Lilly has reported record-breaking weight reduction results from Phase 3 clinical trials evaluating retatrutide, an investigational once-weekly injectable medication. In the 80-week TRIUMPH-1 study of adults with obesity or overweight who do not have diabetes, patients receiving the highest dose experienced an average weight reduction of up to 28.3% under an efficacy analysis, according to Medscape, while Prof. Peptide reports a 25.0% average weight loss under a treatment-regimen analysis published in the New England Journal of Medicine. The findings mark a notable development in the expanding field of metabolic and weight management therapies, though the medication remains unapproved for public prescription.

How the Triple-Hormone Mechanism Works

Unlike early weight management medications that target a single hormone receptor, retatrutide is designed as a single molecule that functions as a triple receptor agonist. According to GlobeNewswire, the drug simultaneously activates three distinct metabolic pathways: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.

By engaging three separate hormonal receptors involved in appetite regulation, blood sugar control, and energy expenditure, researchers aim to address weight loss plateaus often seen with single- or dual-agonist therapies. In the Phase 3 TRIUMPH-1 trial (ClinicalTrials.gov NCT05929066), Eli Lilly funded a randomized, double-blind study enrolling 2,339 adults with obesity or overweight and without diabetes, according to Prof. Peptide. Participants were assigned to receive once-weekly subcutaneous injections of retatrutide at doses of 4 mg, 9 mg, or 12 mg, or a placebo, over an 80-week period.

Breaking Down the TRIUMPH-1 Weight Loss Figures

Reports on the TRIUMPH-1 trial highlight different top-line numbers depending on the statistical method—known as an estimand—used to evaluate the patient data. According to Medscape, participants in the 12 mg group achieved an average weight reduction of 28.3% at 80 weeks when measured using the efficacy estimand, which calculates outcomes assuming participants remained on the medication as directed.

In contrast, Prof. Peptide notes that the published abstract in the New England Journal of Medicine emphasizes the treatment-regimen (intention-to-treat) estimand, which accounts for all randomized participants regardless of whether they discontinued the drug early. Under this treatment-regimen analysis, average weight changes at 80 weeks were:

  • 4 mg dose: 17.6% body weight reduction
  • 9 mg dose: 23.7% body weight reduction
  • 12 mg dose: 25.0% body weight reduction
  • Placebo: 3.9% body weight reduction

Additionally, Prof. Peptide points out that Eli Lilly previously shared a 30.3% average weight loss figure in May based on a 104-week extension analysis. Because the 25.0%, 28.3%, and 30.3% numbers reflect different time points and statistical frameworks, medical analysts emphasize that the figures do not contradict one another, but rather measure separate aspects of the trial data.

Broader Results in Diabetes, Heart Disease, and Joint Pain

Beyond overall body weight in non-diabetic adults, the TRIUMPH clinical program evaluated how retatrutide performs across complex chronic conditions. Within the main TRIUMPH-1 study, investigators tracked two specific patient subgroups for prespecified primary outcomes in the 9 mg and 12 mg groups against placebo: changes in the WOMAC knee-pain score among 574 participants with knee osteoarthritis, and changes in the apnea-hypopnea index among 243 participants diagnosed with obstructive sleep apnea.

Separate Phase 3 trials examined patients with additional metabolic and cardiovascular risks. According to Medscape, the TRIUMPH-2 trial evaluated adults with type 2 diabetes over 80 weeks, demonstrating weight reductions of up to 20.8% in the highest-dose group. Meanwhile, the TRIUMPH-3 trial focused on participants living with severe obesity and established cardiovascular disease, recording an average weight loss of 22.6% at 80 weeks.

Safety Profile, Regulatory Timeline, and Patient Guidance

As with existing medications in the incretin mimetic class, tolerability remains a central question for clinicians and patients. According to the TRIUMPH-1 abstract summarized by Prof. Peptide, the most common adverse events observed during the 80-week trial were gastrointestinal in nature. While specific event rates, serious adverse event counts, and discontinuation percentages were not detailed in the TRIUMPH-1 abstract, the companion TRIUMPH-2 publication in The Lancet includes specific adverse-event rates in its summary.

For patients considering weight management options, public health and clinical reports stress that retatrutide is strictly an investigational compound. According to Lufkin Daily News, the clinical trial results do not establish U.S. Food and Drug Administration (FDA) approval or availability for routine prescribing. Eli Lilly has indicated plans to submit its formal regulatory application in the first quarter of 2027, following an October 2 FDA classification decision regarding the appropriate review pathway.

Because the medication has no regulatory approval anywhere in the world, clinicians warn consumers to avoid unapproved products marketed as retatrutide online. Patients seeking support for obesity, diabetes, or related conditions should consult a licensed healthcare provider to discuss FDA-approved therapies and evidence-based treatment plans.

Frequently Asked Questions

Why do reports cite both 28.3% and 25.0% weight loss for the same trial?

The two numbers come from different statistical analyses of the 80-week TRIUMPH-1 trial for the 12 mg dose. The 28.3% figure comes from the efficacy estimand, which estimates weight loss if all participants stayed on treatment as planned. The 25.0% figure comes from the treatment-regimen estimand, which averages results across all randomized participants, including those who stopped taking the medication early.

What side effects were reported during the retatrutide clinical trials?

According to the published abstract for TRIUMPH-1, the most common side effects were gastrointestinal issues. Full tables detailing exact percentages of mild, moderate, and serious adverse events, as well as how many patients stopped treatment due to side effects, are housed in the full-text medical journal publications rather than the preliminary abstract.

When will retatrutide be available at pharmacies?

Retatrutide is not currently available for prescription. Eli Lilly plans to submit its application to regulators in the first quarter of 2027. The FDA must thoroughly review the complete safety and efficacy data before deciding whether to approve the medication for public use.

Sources